Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial

IMPORTANCE: This study evaluated nilotinib safety and its effects on biomarkers as a potential disease-modifying drug in Parkinson disease. OBJECTIVES: To assess nilotinib effects on safety and pharmacokinetics and measure the change in exploratory biomarkers in patients with moderately severe Parki...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagan, Fernando. L., Hebron, Michaeline L., Wilmarth, Barbara, Torres-Yaghi, Yasar, Lawler, Abigail, Mundel, Elizabeth E., Yusuf, Nadia, Starr, Nathan J., Anjum, Muhammad, Arellano, Joy, Howard, Helen H., Shi, Wangke, Mulki, Sanjana, Kurd-Misto, Tarick, Matar, Sara, Liu, Xiaoguang, Ahn, Jaeil, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990742/
https://www.ncbi.nlm.nih.gov/pubmed/31841599
http://dx.doi.org/10.1001/jamaneurol.2019.4200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990742/
https://www.ncbi.nlm.nih.gov/pubmed/31841599
http://dx.doi.org/10.1001/jamaneurol.2019.4200

Ejemplares similares